Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcturus Therapeutics Holdings (ARCT) Depreciation & Amortization (CF) (2018 - 2025)

Arcturus Therapeutics Holdings' Depreciation & Amortization (CF) history spans 8 years, with the latest figure at $725000.0 for Q4 2025.

  • For Q4 2025, Depreciation & Amortization (CF) fell 11.48% year-over-year to $725000.0; the TTM value through Dec 2025 reached $3.1 million, down 11.17%, while the annual FY2025 figure was $3.0 million, 14.64% down from the prior year.
  • Depreciation & Amortization (CF) reached $725000.0 in Q4 2025 per ARCT's latest filing, down from $800000.0 in the prior quarter.
  • In the past five years, Depreciation & Amortization (CF) ranged from a high of $900000.0 in Q1 2024 to a low of $200000.0 in Q1 2022.
  • Average Depreciation & Amortization (CF) over 5 years is $616800.0, with a median of $712500.0 recorded in 2023.
  • Peak YoY movement for Depreciation & Amortization (CF): plummeted 34.85% in 2022, then soared 200.0% in 2023.
  • A 5-year view of Depreciation & Amortization (CF) shows it stood at $300000.0 in 2021, then soared by 75.67% to $527000.0 in 2022, then surged by 62.62% to $857000.0 in 2023, then decreased by 4.43% to $819000.0 in 2024, then decreased by 11.48% to $725000.0 in 2025.
  • Per Business Quant, the three most recent readings for ARCT's Depreciation & Amortization (CF) are $725000.0 (Q4 2025), $800000.0 (Q3 2025), and $800000.0 (Q2 2025).